冈田酸对喉鳞癌细胞系PP2A活性及迁移的影响

doi:10.3969/j.issn.1004-616x.2016.04.005

癌变·畸变·突变 ›› 2016, Vol. 28 ›› Issue (4): 273-276,280.doi: 10.3969/j.issn.1004-616x.2016.04.005

冈田酸对喉鳞癌细胞系PP2A活性及迁移的影响

童宇圣¹, 陈涛¹, 王聪慧¹, 袁晖², 徐立红³, 林志宏²

1. 浙江大学医学院临床医学二系, 浙江杭州 310058;
2. 浙江大学医学院附属第二医院耳鼻喉科, 浙江杭州 310058;
3. 浙江大学医学院生物化学系, 浙江杭州 310058

收稿日期:2015-10-27 修回日期:2016-03-21 出版日期:2016-07-31 发布日期:2016-07-31
通讯作者: 林志宏,E-mail:lzh@163.com E-mail:lzh@163.com
作者简介:童宇圣,E-mail:tongys@zju.edu.cn;Tel:0571-88208265
基金资助:
浙江省自然科学基金（LY13H130001）；浙江省科技厅项目（2013C33208）；浙江省中医药管理局项目（2012ZA085）

Okadaic acid inhibits PP2A activities and cell migration of laryngeal squamous cell carcinoma Hep-2

TONG Yusheng¹, CHEN Tao¹, WANG Conghui¹, YUAN Hui², XU Lihong³, LIN Zhihong²

1. The Second Department of Clinical Medicine, Zhejiang University School of Medicine, Hangzhou 310058;
2. The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310058;
3. Department of Biochemistry, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China

Received:2015-10-27 Revised:2016-03-21 Online:2016-07-31 Published:2016-07-31

摘要/Abstract

摘要： 目的：探讨冈田酸（OA）对喉鳞癌细胞系（Hep-2）活性和迁移能力的影响及其可能的作用机制。方法：采用四甲基噻唑蓝（MTT）比色实验确定OA作用于Hep-2的最大浓度；酶活性实验检测不同浓度（0、50、100 nmol/L） OA对Hep-2蛋白磷酸酶2A （PP2A）活性的影响；划痕实验检测Hep-2在不同浓度（0、50、100 nmol/L） OA作用下迁移能力的变化。结果：50、100、200 nmol/L OA作用24 h后Hep-2的相对活力分别为96.7%±1.8%、82.9%±12.6%和57.2%±7.7%，与对照组（100%）比较均明显下降（P均<0.05）。50和100 nmol/L OA作用24 h后PP2A的相对活性分别为30.90%±12.01%和8.98%±4.96%，与对照组（100%）相比明显下降（P<0.05）。划痕试验中，经OA作用24及48 h后Hep-2细胞的迁移能力与对照组相比均明显减弱（P<0.05），并且100 nmol/L OA处理组迁移能力的减弱程度较50 nmol/L OA处理组更明显（P<0.05）。结论：100 nmol/L冈田酸明显抑制Hep-2细胞PP2A活性并降低了细胞的迁移能力。

关键词: 冈田酸, Hep-2细胞系, 喉鳞状细胞癌, 蛋白磷酸酶2A, 迁移

Abstract: OBJECTIVE: To investigate the mechanism of inhibition of Hep-2 cell migration by Okadaic acid (OA). METHODS: MTT assay was used to determine the doses of OA for the investigation. Hep-2 cells were treated with 0, 50 or 100 nmol/L OA and enzyme assay was used to measure PP2A activities. Wound scratch assay was used to observe the influence of OA on migration of Hep-2. RESULTS: The growth inhibition ratio was 96.7%±1.8%, 82.9%±12.6% and 57.2%±7.7% in cells treated with 50, 100 and 200 nmol/L OA, and the difference was significant (P<0.05). In cells treated with 50 and 100 nmol/L OA, the relative activity of PP2A was 30.90%±12.01% and 8.98%±4.96% (P<0.05). From the wound scratch assay, the treated cells took significantly longer than untreated cells for healing (P<0.05). CONCLUSION: Inhibition of PP2A activities may be responsible for the reduction of migration in the OA-treated Hep-2 cells.

Key words: Okadaic acid, Hep-2, laryngeal squamous cell carcinoma, protein phosphatase 2A, migration

中图分类号:

R73-3

童宇圣, 陈涛, 王聪慧, 袁晖, 徐立红, 林志宏. 冈田酸对喉鳞癌细胞系PP2A活性及迁移的影响[J]. 癌变·畸变·突变, 2016, 28(4): 273-276,280.

TONG Yusheng, CHEN Tao, WANG Conghui, YUAN Hui, XU Lihong, LIN Zhihong. Okadaic acid inhibits PP2A activities and cell migration of laryngeal squamous cell carcinoma Hep-2[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(4): 273-276,280.

参考文献

[1] Bialojan C,Takai A. Inhibitory effect of a marine-sponge toxin,okadaic acid,on protein phosphatases. Specificity and kinetics[J]. Biochem J,1988,256(1):283-290.
[2] Ito A,Koma Y,Watabe K,et al. A truncated isoform of the protein phosphatase 2A B56γ regulatory subunit may promote genetic instability and cause tumor progression[J]. American J Pathol,2003,162(1):81-91.
[3] Chang YW,Chen MW,Chiu CF,et al. Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-κB signaling in cervical cancer[J]. Ann Surg Oncol,2014,21(Sup 4):687-695.
[4] Gao W,Zhang C,Feng Y,et al. Fascin-1,ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma[J]. PLoS ONE,2012,7(11):e50710.
[5] Wang DS,Pan CC,Lai HC,et al. Expression of HMGA1 and ezrin in laryngeal squamous cell carcinoma[J]. Acta Oto-laryngologica,2013,133(6):626-632.
[6] Hermans R. Staging of laryngeal and hypopharyngeal cancer:value of imaging studies[J]. Eur Radiol,2006,16(11):2386-2400.
[7] Staser K,Shew MA,Michels EG,et al. A Pak1-PP2A-ERM signaling axis mediates F-actin rearrangement and degranulation in mast cells[J]. Exp Hematol,2013,41(1):56-66.
[8] McDermott MS,Browne BC,Conlon NT,et al. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy[J]. Mol Cancer,2014,13(1):4072-4080.
[9] Becsi B,Kiss A,Erdodi F. Interaction of protein phosphatase inhibitors with membrane lipids assessed by surface plasmon resonance based binding technique[J]. Chem Phys Lipids,2014;183c:68-76.
[10] Oteri G,Stammati A,Zampaglioni F,et al. Evaluation of the use of two human cell lines for Okadaic acid and DTX-1 determination by cytotoxicity assays and damage characterization[J]. Nat Toxins,1998,6(5):197-209.
[11] Schlecht NF,Brandwein-Gensler M,Smith RV,et al. Cyto-plasmic Ezrin and Moesin correlate with poor survival in head and neck squamous cell carcinoma[J]. Head Neck Pathol,2012,6:232-243.
[12] 林丽娜,林育纯,陈慧峰,等. PP2A-B56γ高表达抑制镉诱导的人肝L02细胞DNA损伤[J]. 癌变·畸变·突变,2012,24(3):189-194.
[13] Janghorban M,Farrell AS,Allen-Petersen BL,et al. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer[J]. PNAS,2014,111(25):9157-9162.
[14] Wandzioch E,Pusey M,Werda A,et al. PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells[J]. Cancer Res,2014,74(16):4295-4305
[15] Wei L,Qu W,Sun J,et al. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin[J]. Cancer Gene Ther,2014,21(5):194-199.
[16] Li J,Sheng C,Li W,et al. Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma[J]. Int J Exp Pathol,2014,7(3):1147-1153.
[17] Wu MY,Xie X,Xu ZK,et al. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/beta-catenin pathway by phosphorylation and degradation of beta-catenin[J]. Oncol Rep,2014,32(2):513-522.
[18] Farrell AS,Allen-Petersen B,Daniel CJ,et al. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer[J]. Mol Cancer Res,2014,12(6):924-939.

冈田酸对喉鳞癌细胞系PP2A活性及迁移的影响

Okadaic acid inhibits PP2A activities and cell migration of laryngeal squamous cell carcinoma Hep-2

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵岩, 孙震晓. 二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究[J]. 癌变·畸变·突变, 2022, 34(1): 35-39.
[2]	杨兴肖, 张雪原, 邹乃祎, 单保恩, 马鸣, 祝淑钗. 干扰HMGB1基因表达对食管鳞癌细胞侵袭迁移及放射敏感性的影响[J]. 癌变·畸变·突变, 2021, 33(5): 327-333.
[3]	王琛瑶, 梁百慧, 吴锦源, 唐梓涵, 许小文, 尹梓健, 丁雅琼, 方雄钊, 李栢芝, 文姝佚, 程转, 詹涵, 张粤烽, 王泫哲, 何仕龙, 张可洵, 刘雅骐, 周飞, 熊兴东, 白春英, 许丽艳, 李恩民. RAC1对恶性肿瘤的调控作用及其分子机制研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 401-404.
[4]	陈绵龄, 马硕一. miR-21通过靶向PDCD4调控三阴性乳腺癌细胞的迁移和侵袭[J]. 癌变·畸变·突变, 2020, 32(4): 292-297.
[5]	姜晓燕, 刘淑娟, 闫冬, 何映雪, 丁库克. 锶在土培辣椒不同器官中的富集与迁移规律[J]. 癌变·畸变·突变, 2020, 32(4): 309-311,316.
[6]	方从文, 石莹, 杜凤, 康秉文, 韩明博, 殷草草, 柏桦, 秦绪军. 高迁移率族蛋白B1在小鼠肝再生中对细胞增殖的作用及机制[J]. 癌变·畸变·突变, 2020, 32(2): 81-86.
[7]	陈婉娴, 王思梦, 陈张瑜, 王潘集, 许丽艳, 李恩民. 细胞分裂周期蛋白42在肿瘤中的作用及其分子机制研究进展[J]. 癌变·畸变·突变, 2020, 32(2): 159-161.
[8]	盛磊, 武贵臻, 热娜古丽·热依木, 艾尼娃尔·艾克木. 新疆黑种草子总黄酮体外抗宫颈癌活性研究[J]. 癌变·畸变·突变, 2019, 31(5): 385-391.
[9]	王晓杰, 滕宇, 顾勐, 王子宇, 赵晓婷, 岳文涛. ROCK1基因敲除对乳腺癌细胞系迁移及侵袭的影响[J]. 癌变·畸变·突变, 2019, 31(3): 193-197,202.
[10]	车琳, 林忠宁, 林育纯. 蛋白磷酸酶2A在线粒体质量控制中的作用研究进展[J]. 癌变·畸变·突变, 2019, 31(1): 73-78.
[11]	闫冬, 丁库克, 何映雪, 范莉, 姜晓燕. 3种植物在水培方式下对锶的富集和迁移实验研究[J]. 癌变·畸变·突变, 2019, 31(1): 64-68.
[12]	邢龙, 李杨, 马小龙, MOHAMMED H, 黄莹, 谢富强, 冯正虎. 抗肿瘤新药乙烷硒啉对人舌鳞状细胞癌细胞增殖和迁移的影响[J]. 癌变·畸变·突变, 2018, 30(4): 279-285.
[13]	马帮靖, 郝翔麟, 韩飞, 陈洪强, 刘晋祎, 曹佳, 张爱华. SOX30基因调控桥粒基因DSC3抑制肺腺癌的增殖与迁移[J]. 癌变·畸变·突变, 2018, 30(3): 165-170,175.
[14]	李雨轩, 李凯, 张彤彤, 郭元彪, 殷俊, 包勇. 热休克蛋白HDJ1 影响肺腺癌细胞侵袭和迁移能力的研究[J]. 癌变·畸变·突变, 2017, 29(5): 358-363.
[15]	张静, 滕宇, 赵晓婷, 江妹, 岳文涛. Wnt蛋白生成抑制剂2对非小细胞肺癌细胞迁移与侵袭能力的影响[J]. 癌变·畸变·突变, 2017, 29(4): 245-250.